Cargando…

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study

The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shousheng, Jiang, Chang, Yang, Lin, Huang, Jinsheng, Peng, Roujun, Wang, Xiaopai, He, Wenzhuo, Bai, Long, Zhou, Yixin, Zhang, Bei, Xia, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378223/
https://www.ncbi.nlm.nih.gov/pubmed/32704062
http://dx.doi.org/10.1038/s41598-020-69230-5
_version_ 1783562369354432512
author Liu, Shousheng
Jiang, Chang
Yang, Lin
Huang, Jinsheng
Peng, Roujun
Wang, Xiaopai
He, Wenzhuo
Bai, Long
Zhou, Yixin
Zhang, Bei
Xia, Liangping
author_facet Liu, Shousheng
Jiang, Chang
Yang, Lin
Huang, Jinsheng
Peng, Roujun
Wang, Xiaopai
He, Wenzhuo
Bai, Long
Zhou, Yixin
Zhang, Bei
Xia, Liangping
author_sort Liu, Shousheng
collection PubMed
description The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups. PFS 1nd was comparable (10.0 vs 10.4 months; p = 0.402), while PFS 2nd (4.6 vs 7.9 months; p = 0.002), OS 1nd (26.8 vs 40.0 months; p = 0.011), and OS 2nd (15.2 vs 22.3 months; p = 0.006) were all poorer in group A compared with group B. Our study in combination with previous clinical data suggest that first-line application of cetuximab may provide a favorable condition for promoting the effect of subsequent bevacizumab, thus representing the optimal targeted therapy sequence in patients of RAS wild-type left-sided mCRC.
format Online
Article
Text
id pubmed-7378223
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73782232020-07-24 First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study Liu, Shousheng Jiang, Chang Yang, Lin Huang, Jinsheng Peng, Roujun Wang, Xiaopai He, Wenzhuo Bai, Long Zhou, Yixin Zhang, Bei Xia, Liangping Sci Rep Article The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups. PFS 1nd was comparable (10.0 vs 10.4 months; p = 0.402), while PFS 2nd (4.6 vs 7.9 months; p = 0.002), OS 1nd (26.8 vs 40.0 months; p = 0.011), and OS 2nd (15.2 vs 22.3 months; p = 0.006) were all poorer in group A compared with group B. Our study in combination with previous clinical data suggest that first-line application of cetuximab may provide a favorable condition for promoting the effect of subsequent bevacizumab, thus representing the optimal targeted therapy sequence in patients of RAS wild-type left-sided mCRC. Nature Publishing Group UK 2020-07-23 /pmc/articles/PMC7378223/ /pubmed/32704062 http://dx.doi.org/10.1038/s41598-020-69230-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Shousheng
Jiang, Chang
Yang, Lin
Huang, Jinsheng
Peng, Roujun
Wang, Xiaopai
He, Wenzhuo
Bai, Long
Zhou, Yixin
Zhang, Bei
Xia, Liangping
First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title_full First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title_fullStr First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title_full_unstemmed First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title_short First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
title_sort first-line cetuximab improves the efficacy of subsequent bevacizumab for ras wild-type left-sided metastatic colorectal cancer: an observational retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378223/
https://www.ncbi.nlm.nih.gov/pubmed/32704062
http://dx.doi.org/10.1038/s41598-020-69230-5
work_keys_str_mv AT liushousheng firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT jiangchang firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT yanglin firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT huangjinsheng firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT pengroujun firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT wangxiaopai firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT hewenzhuo firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT bailong firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT zhouyixin firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT zhangbei firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy
AT xialiangping firstlinecetuximabimprovestheefficacyofsubsequentbevacizumabforraswildtypeleftsidedmetastaticcolorectalcanceranobservationalretrospectivestudy